Oxy-bridged bicyclo-[2.2. 1]-heptene compound containing different sulfanilamide nitrogen atom substituents and preparation method and application of oxygen-bridged bicyclo-[2.2. 1]-heptene compound
By developing oxygen-bridge bicyclic-[2.2.1]-heptene compounds containing different sulfonanionic atom substituents, the side effects and drug resistance of existing anti-breast cancer drugs have been solved, and the effectiveness of estrogen receptors has been achieved. Inhibition provides a new mechanism of anti-breast cancer treatment.
Patent Information
- Application Number
- CN202410946559.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-16
AI Technical Summary
The existing antiestrogenic drugs have side effects and drug resistance problems in the treatment of breast cancer, and new mechanisms of target drugs are needed to develop targeted drugs for treatment of estrogen receptors.
Develop oxygen-bridge bicyclic-[2.2.1]-heptene compounds containing different sulfonamide atom substituents, and perform diene synthesis by synthesizing 3,4-bis(4-hydroxyphenyl)-furan and ethylene sulfonamide derivatives , oxygen-bridged bicyclic-[2.2.1]-heptene compounds with inhibitory activity were prepared to enhance their affinity for estrogen receptors and interfere with their dimerization interface.
The compound showed inhibitory activity against wild-type breast cancer cells and drug-resistant mutant cells, especially compounds containing fluorine or chlorine atoms substituted on the benzene ring further enhanced its affinity for estrogen receptors, providing a new mechanism Estrogen receptor inhibitors that are antibrother cancer drug-resistant mutations.
Smart Images

Figure BDA0004945828680000011 
Figure BDA0004945828680000013 
Figure BDA0004945828680000014
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to a class of oxygen-bridged bicyclic-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents, and a preparation method and application thereof. Background Art
[0002] In recent years, breast cancer has become one of the most common cancers in women, and the overexpression of estrogen receptors can lead to breast cancer, so anti-estrogen drugs are constantly being developed and used. However, studies have shown that long-term use of anti-estrogen drugs can cause strong side effects and lead to the development of drug-resistant breast cancer. Therefore, it is necessary to develop anti-breast cancer drugs with new mechanisms targeting estrogen receptors. Summary of the invention
[0003] The purpose of the present invention is to provide an oxygen-bridged bicyclo-[2.2.1]-heptene compound containing different sulfonamide nitrogen atom substituents, which can at least solve some of the defects existing in the prior art.
[0004] To achieve the above object, the present invention adopts the following technical solution:
[0005] Oxygen-bridged bicyclic-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents have the following general structure:
[0006]
[0007] wherein X is selected from -H, -F or -Cl;
[0008] R 2 Selected from
[0009] R 1 Selected from
[0010] Preferably, the oxygen-bridged bicyclo-[2.2.1]-heptene compound containing different sulfonamide nitrogen atom substituents is selected from any one of the following compounds:
[0011] 5,6-Bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-N-propyl-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0012] 5,6-Bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-N-(3,3,3-trifluoropropyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0013] 5,6-Bis(4-hydroxyphenyl)-N-isobutyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0014] 5,6-Bis(4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0015] N-allyl-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0016] N-(2-Hydroxyethyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0017] N-(2-Fluoro-2-methylpropyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0018] N-(Cyclopropylmethyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0019] N-(Cyclobutylmethyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0020] N-cyclohexyl-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0021] 5,6-Bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-N-phenyl-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0022] N-Benzyl-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0023] 4,4'-(5-(indolin-1-ylsulfonyl)-7-oxabicyclo[2.2.1]hept-2-ene-2,3-diyl)diphenol;
[0024] 4,4'-(5-((6-methoxy-3,4-dihydroquinolin-1(2H)-yl)sulfonyl)-7-oxabicyclo[2.2.1]hept-2-ene-2,3-diyl)diphenol;
[0025] 4,4'-(5-((3,4-dihydroquinolin-1(2H)-yl)sulfonyl)-7-oxabicyclo[2.2.1]hept-2-ene-2,3-diyl)diphenol;
[0026] 5,6-Bis(3-fluoro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0027] N-(Cyclopropylmethyl)-5,6-bis(3-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0028] N-(Cyclobutylmethyl)-5,6-bis(3-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0029] N-cyclohexyl-5,6-bis(3-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0030] 5,6-Bis(3-chloro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0031] 5,6-Bis(3-chloro-4-hydroxyphenyl)-N-(cyclopropylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0032] 5,6-Bis(3-chloro-4-hydroxyphenyl)-N-(cyclobutylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0033] 5,6-Bis(3-chloro-4-hydroxyphenyl)-N-cyclohexyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0034] 5,6-Bis(2-fluoro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0035] O-(Cyclopropylmethyl)-5,6-bis(2-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0036] N-(Cyclobutylmethyl)-5,6-bis(2-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0037] N-cyclohexyl-5,6-bis(2-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0038] 5,6-Bis(2-chloro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0039] 5,6-Bis(2-chloro-4-hydroxyphenyl)-N-(cyclopropylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0040] 5,6-Bis(2-chloro-4-hydroxyphenyl)-N-(cyclobutylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide;
[0041] 5,6-Bis(2-chloro-4-hydroxyphenyl)-N-cyclohexyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide.
[0042] In addition, the present invention also provides a method for preparing the above-mentioned oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents, comprising the following steps:
[0043] S1. Synthesizing 3,4-bis(4-hydroxyphenyl)-furan, or synthesizing 3,4-bis(4-hydroxyphenyl)-furan containing different halogen substitutions;
[0044] S2. Synthesis of vinylsulfonamide derivatives;
[0045] S3. The 3,4-bis(4-hydroxyphenyl)-furan or 3,4-bis(4-hydroxyphenyl)-furan containing different halogen substitutions synthesized in step S1 is subjected to a diene synthesis reaction with the ethylene sulfonamide derivative synthesized in step S2 to obtain an oxygen-bridged bicyclo-[2.2.1]-heptene compound containing different sulfonamide nitrogen atom substituents.
[0046] Specifically, in step S1, the synthesis route of 3,4-bis(4-hydroxyphenyl)-furan is as follows:
[0047]
[0048] 1) Synthesis of p-methoxybromoacetophenone
[0049] Weigh p-methoxyacetophenone, p-toluenesulfonic acid and N-bromosuccinimide in a reaction container, add dichloromethane to dissolve, react the dissolved and mixed reactants at room temperature, monitor whether the reaction is complete by TLC thin layer chromatography, desolventize after the reaction is complete, add ethyl acetate to dissolve, wash with 2N dilute hydrochloric acid, saturated sodium bicarbonate and saturated sodium chloride in turn, and remove the organic layer by anhydrous NaSO 4 Dry, filter and spin-dry to obtain a crude product, which is purified by column chromatography to obtain a white solid compound 2, namely p-methoxybromoacetophenone;
[0050] 2) Synthesis of 2-(4-methoxyphenyl)-2-carbonylethyl-2-(4-methoxyphenyl) acetate
[0051] Weigh p-methoxybromoacetophenone and p-methoxyphenylacetic acid in a reaction container, add anhydrous acetonitrile to dissolve, slowly add anhydrous triethylamine dropwise, continue the reaction at room temperature, monitor whether the reaction is complete by TLC thin-layer chromatography, evaporate acetonitrile and triethylamine after the reaction is complete, add ethyl acetate to dissolve, wash with 2N dilute hydrochloric acid, saturated sodium bicarbonate and saturated sodium chloride successively, dry the organic layer with anhydrous sodium sulfate, filter and spin-dry to obtain a crude product, and purify it by column chromatography to obtain a yellow solid compound 4, i.e. 2-(4-methoxyphenyl)-2-carbonylethyl-2-(4-methoxyphenyl) acetate;
[0052] 3) Synthesis of 3,4-di(4-methoxy-phenyl)furan-2-one
[0053] Anhydrous and oxygen-free operation, under argon, weigh 2-(4-methoxyphenyl)-2-carbonylethyl-2-(4-methoxyphenyl) acetate in a reaction container, add anhydrous dimethyl sulfoxide solvent to dissolve, slowly add 80% NaH, react at 25°C, use TLC thin layer chromatography to monitor whether the reaction is complete, after the reaction is complete, add 2N dilute hydrochloric acid to quench the reaction, extract the reaction solution with ethyl acetate, and the organic layer is anhydrous NaSO 4 Drying, desolvation under reduced pressure to obtain a crude product, and then purification by silica gel column to obtain compound 5, namely 3,4-di(4-methoxy-phenyl)furan-2-one;
[0054] 4) Synthesis of 3,4-bis(4-hydroxy-phenyl)furan-2-one
[0055] Under anhydrous and oxygen-free conditions, weigh 3,4-di(4-methoxy-phenyl)furan-2-one in a reaction vessel, add dichloromethane to dissolve it, and add BBr at -20°C. 3 After 12 h of reaction, water was added to quench the reaction, and the reaction solution was extracted with ethyl acetate and washed with saturated NaHCO 3 The organic layer was washed with anhydrous NaSO 4Drying, desolvation under reduced pressure to obtain a crude product, and then purification on a silica gel column to obtain compound 6, namely 3,4-bis(4-hydroxy-phenyl)furan-2-one;
[0056] 5) Synthesis of 3,4-bis(4-hydroxy-phenyl)furan
[0057] Under anhydrous and oxygen-free conditions, 3,4-di(4-hydroxy-phenyl)furan-2-one was weighed into a reaction vessel under argon gas. Diisobutyl ether was added to the reaction vessel at -78°C for 12 h. Then, 4% H 2 SO 4 The reaction was quenched, the reaction solution was extracted with ethyl acetate, and washed with saturated NaCl solution. The organic layer was anhydrous NaSO 4 The crude product was dried and desolvated under reduced pressure, and then purified on a silica gel column to obtain compound 7, namely 3,4-bis(4-hydroxy-phenyl)furan.
[0058] Specifically, in step S1, the synthesis route of 3,4-bis(4-hydroxyphenyl)-furan containing different halogen substitutions is as follows:
[0059]
[0060] 1) Synthesis of 3,4-dibromofuran
[0061] Weigh (E)-3,4-dibromohex-3-ene-1,6-diol, add potassium dichromate and concentrated sulfuric acid, and then perform steam distillation to obtain compound 9, i.e., 3,4-dibromofuran;
[0062] 2) Synthesis of halogen-substituted 3,4-bis(4-methoxyphenyl)-furan
[0063] Weigh 3,4-dibromofuran and the corresponding halogen-substituted p-methoxyphenylboronic acid into a reaction container, add a palladium catalyst and anhydrous tetrahydrofuran, heat to reflux, and monitor whether the reaction is complete by TLC thin-layer chromatography. After the reaction is complete, distill off the tetrahydrofuran, add ethyl acetate to dissolve, wash with 2N dilute hydrochloric acid, saturated sodium bicarbonate and saturated sodium chloride in turn, dry the organic layer with anhydrous sodium sulfate, filter and spin-dry to obtain a crude product, and purify it by column chromatography to obtain the corresponding compounds 11a~11d, i.e., halogen-substituted 3,4-di(4-methoxyphenyl)-furan;
[0064] 3) Synthesis of halogen-substituted 3,4-bis(4-hydroxyphenyl)-furan:
[0065] Anhydrous and oxygen-free operation, under argon, weigh halogen-substituted 3,4-di(4-methoxyphenyl)-furan into a reaction vessel, add dichloromethane to dissolve, add BBr at -20°C 3After 12 h of reaction, water was added to quench the reaction, and the reaction solution was extracted with ethyl acetate and washed with saturated NaHCO 3 The organic layer was washed with anhydrous NaSO 4 The crude product was dried and desolventized under reduced pressure, and then purified on a silica gel column to obtain compounds 12a to 12d, namely halogen-substituted 3,4-bis(4-hydroxyphenyl)-furan.
[0066] Specifically, in step S2, the synthesis route of the vinylsulfonamide derivative is as follows:
[0067]
[0068] 1) Synthesis of N-phenylacetamide compounds 15a-15c
[0069] Weigh p-methoxyaniline and acid anhydride compounds 14a-14c into a single-mouth bottle, add dichloromethane to dissolve, slowly add pyridine, continue the reaction at room temperature, and use TLC thin-layer chromatography to monitor whether the reaction is complete. After the reaction is complete, remove the solvent under reduced pressure to obtain a crude product, and purify it with a silica gel column to obtain N-phenylacetamide compounds 15a-15c;
[0070] 2) Synthesis of N-alkylaniline compounds 16a to 16d
[0071] Under argon protection, N-phenylacetamide compounds 15a-15c were weighed into a double-necked bottle, anhydrous tetrahydrofuran was added to dissolve, borane-tetrahydrofuran was slowly added dropwise at 0°C, the temperature was slowly raised to 60°C and reacted for 24 hours, methanol was added to quench the reaction, the reaction solution was decompressed and desolventized to obtain a crude product, which was purified by silica gel column to obtain a white oily substance, namely N-alkylaniline compounds 16a-16d;
[0072] 3) Synthesis of sulfonamide dienophiles 17a-17d
[0073] The corresponding N-alkylaniline compounds 16a-16d were weighed and dissolved in dichloromethane, 2-chloroethanesulfonyl chloride was slowly added at 0°C, and after reacting for 10 minutes, a 20% sodium hydroxide aqueous solution was slowly added dropwise, and after reacting at room temperature for 24 hours, the solvent was removed under reduced pressure to obtain a crude product, which was purified by a silica gel column to obtain sulfonamide dienophile compounds 17a-17d;
[0074] 4) Synthesis of sulfonamide dienophile compound 18
[0075] Weigh p-methoxyaniline and dissolve it in dichloromethane. Slowly add 2-chloroethanesulfonyl chloride at 0°C. After reacting for 10 minutes, slowly add 20% sodium hydroxide aqueous solution dropwise. After reacting at room temperature for 24 hours, remove the solvent under reduced pressure to obtain a crude product. Purify it on a silica gel column to obtain sulfonamide dienophile compound 18.
[0076] 5) Synthesis of sulfonamide dienophile compounds 20a-20i
[0077] The sulfonamide dienophile compound 18 was weighed and dissolved in N,N-dimethylformamide, potassium carbonate was added, and then the corresponding bromoalkanes 19a-19i were slowly added. After reacting at 60°C for 24 hours, the solvent was removed under reduced pressure to obtain a crude product, which was purified by a silica gel column to obtain the sulfonamide dienophile compounds 20a-20i;
[0078] 6) Synthesis of sulfonamide dienophile compounds 22a to 22c
[0079] The corresponding amine compounds 21a~21c were weighed and dissolved in dichloromethane, 2-chloroethanesulfonyl chloride was slowly added at 0°C, and after reacting for 10 minutes, a 20% sodium hydroxide aqueous solution was slowly added dropwise. After reacting at room temperature for 24 hours, the solvent was removed under reduced pressure to obtain a crude product, which was purified by silica gel column to obtain sulfonamide dienophile compounds 22a~22c.
[0080] Specifically, in step S3, the synthesis route of the oxygen-bridged bicyclic-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents is as follows:
[0081]
[0082] Among them, R 1 for R 2 for
[0083] The synthesized 3,4-di(4-hydroxy-phenyl)furan and any one of the ethylenesulfonamide derivatives 17a-17c, 20a-20i, 22a-22c are dissolved in tetrahydrofuran and reacted at 90°C in one step to prepare oxygen-bridged bicyclo-[2.2.1]-heptene compounds 23a-23o with different sulfonamide nitrogen atom substituents.
[0084] Specifically, in step S3, the synthesis route of the oxygen-bridged bicyclic-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents is as follows:
[0085]
[0086] The synthesized 3,4-di(4-hydroxyphenyl)-furan containing different halogen substitutions and any one of the ethylenesulfonamide derivatives 17c, 20e, 20f, 20g are dissolved in tetrahydrofuran and reacted at 90°C in one step to prepare oxygen-bridged bicyclo-[2.2.1]-heptene compounds 24a~24p containing different sulfonamide nitrogen atom substituents.
[0087] In addition, the present invention also provides the use of the above oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents and pharmaceutically acceptable salts thereof in the preparation of anti-breast cancer drugs.
[0088] Furthermore, the anti-breast cancer drug comprises one or more pharmaceutically acceptable carriers or excipients of the oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents.
[0089] Compared with the prior art, the present invention has the following beneficial effects:
[0090] The invention uses 3,4-bis(4-hydroxyphenyl)-furan or 3,4-bis(4-hydroxyphenyl)-furan containing different halogen substitutions and a dienophile compound containing different sulfonamide nitrogen atom substituents as raw materials, and prepares oxygen-bridged bicyclic-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents by a one-step reaction. Such compounds show certain inhibitory activity and protein degradation activity against wild-type breast cancer cells MCF-7, three drug-resistant mutant breast cancer cells MCF-7Y537S, MCF-7D538G, and MCF-7EGFR; and oxygen-bridged bicyclic-[2.2.1]-heptene compounds containing fluorine atoms or chlorine atoms substituted on the benzene ring further enhance the affinity for the estrogen receptor and interfere with the dimerization interface of the estrogen receptor, thereby providing an estrogen receptor inhibitor with a new mechanism for resisting drug-resistant mutations of breast cancer. DETAILED DESCRIPTION
[0091] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0092] 1. Synthesis of 3,4-bis(4-hydroxyphenyl)-furan compound 7:
[0093]
[0094] a. Synthesis of p-methoxybromoacetophenone compound 2
[0095] Weigh 1.0 eq. of p-methoxyacetophenone 1, 0.2 eq. of p-toluenesulfonic acid, and 1.2 eq. of N-bromosuccinimide (NBS) in a 50 mL round-bottom flask, and add 20 mL of CH 2 Cl 2 After 9 h of reaction at room temperature, the reaction was complete after monitoring by TLC thin-layer chromatography. The solvent was removed under reduced pressure, 50 mL of ethyl acetate was added to dissolve, and 3.0 eq. 2N HCl and 2 × 30 mL of saturated NaHCO 3 The solution was washed with 30 mL of saturated NaCl and the organic layer was washed with anhydrous NaSO 4 Dry, filter and spin-dry to obtain a crude product, which was purified by column chromatography to obtain a white solid compound 2.
[0096] b. Synthesis of 2-(4-methoxyphenyl)-2-carbonylethyl-2-(4-methoxyphenyl) acetate compound 4
[0097] 1.0 eq. of compound 2 and 1.0 eq. of p-methoxyphenylacetic acid 3 were weighed into a 50 mL round-bottom flask, 25 mL of anhydrous acetonitrile was added, 1.0 eq. of anhydrous triethylamine (TEA) was slowly added dropwise, and the reaction was continued at room temperature for 2 h. The reaction was monitored to be complete by TLC thin-layer chromatography. After the reaction was completed, acetonitrile and triethylamine were evaporated, ethyl acetate was added to dissolve, and the mixture was washed with 5.0 eq. of 2N dilute hydrochloric acid, 2×30 mL of saturated sodium bicarbonate and 30 mL of saturated sodium chloride. The organic layer was dried over anhydrous sodium sulfate, filtered and dried to obtain a crude product, which was purified by column chromatography to obtain a yellow solid compound 4.
[0098] c. Synthesis of 3,4-di(4-methoxy-phenyl)furan-2-one compound 5
[0099] A 25 mL two-necked bottle and a magnetic bar were baked at 105°C for 15 min. The device was set up while hot and operated in anhydrous and oxygen-free conditions. Under Ar flow, 1.0 eq. of compound 4 was weighed, 10 mL of anhydrous dimethyl sulfoxide (DMSO) was added, 2.0 eq. of 80% NaH was slowly added dropwise, and the reaction was carried out at 25°C for 2 h. After monitoring the reaction completion by TLC thin-layer chromatography, 5 mL of 4.0 eq. of 2N HCl was added to quench the reaction, and the organic layer was extracted with 3×25 mL of ethyl acetate. The organic layer was anhydrous NaSO 4 The crude product was dried and desolvated under reduced pressure, and purified on a silica gel column (petroleum ether / ethyl acetate = 9:1) to obtain compound 5.
[0100] d. Synthesis of 3,4-di(4-hydroxy-phenyl)furan-2-one compound 6
[0101] After baking a 100 mL single-mouth bottle and a magnetic bar at 105°C for 15 min, while the device is hot, operate in anhydrous and oxygen-free conditions, and under Ar flow, weigh 1.0 eq. of compound 5, add 25 mL of dichloromethane (DCM), and add 6.0 eq. of BBr at -20°C. 3 After 12 h of reaction, 10 mL of water was added to quench the reaction, and the mixture was extracted with 3 × 20 mL of ethyl acetate and 15 mL of saturated NaHCO 3 The organic layer was washed with anhydrous NaSO 4 The crude product was dried and desolvated under reduced pressure, and purified on a silica gel column (petroleum ether / ethyl acetate = 7:3) to obtain compound 6.
[0102] e. Synthesis of 3,4-bis(4-hydroxy-phenyl)furan compound 7
[0103] After baking a 50 mL single-mouth bottle and a magnetic bar at 105°C for 15 min, while the device is hot, operate in anhydrous and oxygen-free conditions, and under Ar flow, weigh 1.0 eq. of compound 6, wherein 4.0 eq. of diisobutylaluminum hydride (DIBAL-H) is added at -78°C and reacted for 12 h, then 4% H 2 SO 4 The reaction was quenched and extracted with 3 × 25 mL of ethyl acetate, washed with 30 mL of saturated NaCl solution, and the organic layer was anhydrous NaSO 4 The crude product was dried and desolvated under reduced pressure, and purified on a silica gel column (petroleum ether / ethyl acetate = 6:4) to obtain compound 7.
[0104] 2. Synthesis of 3,4-bis(4-hydroxyphenyl)-furan compounds containing different halogen substitutions
[0105]
[0106] a. Synthesis of 3,4-dibromofuran 9:
[0107] Weigh (E)-3,4-dibromohex-3-ene-1,6-diol, add potassium dichromate and concentrated sulfuric acid, and then perform steam distillation to obtain 3,4-dibromofuran.
[0108] b. Synthesis of halogen-substituted 3,4-di(4-methoxyphenyl)-furan compounds 11a to 11d:
[0109] Weigh 1.0 eq. 3,4-dibromofuran and 4.0 eq. of the corresponding halogen-substituted p-methoxyphenylboronic acid into a 50 mL round-bottom flask, add 0.02 eq. of palladium catalyst (Pd(dppf) 2 Cl 2), add 10 mL of anhydrous tetrahydrofuran (THF), heat to reflux, and monitor the completion of the reaction by TLC thin-layer chromatography. After the reaction is completed, THF is evaporated off, ethyl acetate is added to dissolve, and the mixture is washed with 5.0 eq. 2N dilute hydrochloric acid, 2×30 mL of saturated sodium bicarbonate and 30 mL of saturated sodium chloride. The organic layer is dried over anhydrous sodium sulfate, filtered and spin-dried to obtain a crude product, which is purified by column chromatography to obtain the corresponding compounds 11a~11d.
[0110] c. Synthesis of halogen-substituted 3,4-bis(4-hydroxyphenyl)-furan compounds 12a to 12d:
[0111] After baking a 100 mL single-mouth bottle and a magnetic bar at 105°C for 15 min, while the device is hot, operate in anhydrous and oxygen-free conditions, and under Ar flow, weigh 1.0 eq. of compound 11a-11d, add 25 mL of dichloromethane (DCM), and add 6.0 eq. of BBr at -20°C. 3 After 12 h of reaction, 10 mL of water was added to quench the reaction, and the mixture was extracted with 3 × 20 mL of ethyl acetate and 15 mL of saturated NaHCO 3 The organic layer was washed with anhydrous NaSO 4 The crude product was dried and desolvated under reduced pressure, and purified by silica gel column (petroleum ether / ethyl acetate=7:3) to obtain compounds 12a-12d.
[0112] 3. Synthesis of Ethylene Sulfonamide Derivatives
[0113]
[0114] a. Synthesis of N-phenylacetamide compounds 15a-15c:
[0115] 1 eq. of p-methoxyaniline 13 and 2 eq. of anhydride compounds 14a-14c were weighed into a 100 mL single-necked bottle, 40 mL of dichloromethane (DCM) was added to dissolve them, and then 0.1 eq. of pyridine was slowly added. The reaction was continued at room temperature for 2 h. After the reaction was completed as monitored by TLC thin-layer chromatography, the solvent was removed under reduced pressure to obtain a crude product, which was purified by silica gel column (petroleum ether / ethyl acetate = 15:1) to obtain acetamide compounds 15a-15c.
[0116] b. Synthesis of N-alkylaniline compounds 16a to 16c:
[0117] Under Ar protection, 1 eq. of acetamide compounds 15a-15c were weighed into a 100 mL double-necked bottle, 20 mL of anhydrous tetrahydrofuran (THF) was added to dissolve, and 4 eq. of borane-tetrahydrofuran (BH 3-THF), slowly heated to 60°C and reacted for 24h, then 5mL of methanol was added to quench the reaction; the crude product was obtained after desolventizing under reduced pressure, and purified by silica gel column (petroleum ether / ethyl acetate=12:1) to obtain a white oily substance, i.e., N-alkylaniline compounds 16a~16c.
[0118] c. Synthesis of sulfonamide dienophile compounds 17a to 17c:
[0119] 1 eq. of the corresponding N-alkylaniline compounds 16a-16c were weighed and dissolved in 25 mL of dichloromethane (DCM), and 1.2 eq. of 2-chloroethanesulfonyl chloride was slowly added at 0°C. After reacting for 10 min, a 20% aqueous sodium hydroxide solution was slowly added dropwise. After reacting at room temperature for 24 h, the solvent was removed under reduced pressure to obtain a crude product, which was purified by a silica gel column (petroleum ether / ethyl acetate = 15:1-3:2) to obtain sulfonamide dienophile compounds 17a-17c.
[0120] d. Synthesis of sulfonamide dienophile compound 18:
[0121] The same synthesis as the above acetamide compounds 15a-15c was performed. 1 eq. of p-methoxyaniline 13 was dissolved in 25 mL of dichloromethane. 1.2 eq. of 2-chloroethanesulfonyl chloride was slowly added at 0°C. After reacting for 10 min, a 20% aqueous sodium hydroxide solution was slowly added dropwise. After reacting at room temperature for 24 h, the solvent was removed under reduced pressure to obtain a crude product, which was purified by a silica gel column (petroleum ether / ethyl acetate = 15:1-3:2) to obtain a sulfonamide dienophile compound 18.
[0122] e. Synthesis of sulfonamide dienophile compounds 20a to 20i:
[0123] 1 eq. of the corresponding sulfonamide dienophile compound 18 was weighed and dissolved in 25 mL of N,N-dimethylformamide (DMF), 1.2 eq. of potassium carbonate was added, and then the corresponding bromoalkanes 19a to 19i were slowly added. After reacting at 60°C for 24 h, the solvent was removed under reduced pressure to obtain a crude product, which was purified by a silica gel column (petroleum ether / ethyl acetate = 15:1 to 3:2) to obtain sulfonamide dienophile compounds 20a to 20i.
[0124] f. Synthesis of sulfonamide dienophile compounds 22a to 22c:
[0125] 1 eq. of the corresponding amine compounds 21a-21c were weighed and dissolved in 25 mL of dichloromethane (DCM), and 1.2 eq. of 2-chloroethanesulfonyl chloride was slowly added at 0°C. After reacting for 10 min, a 20% aqueous sodium hydroxide solution was slowly added dropwise. After reacting at room temperature for 24 h, the solvent was removed under reduced pressure to obtain a crude product, which was purified by a silica gel column (petroleum ether / ethyl acetate = 15:1-3:2) to obtain sulfonamide dienophile compounds 22a-22c.
[0126] Embodiment 1:
[0127] This example provides a 5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-N-propyl-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 23a, the chemical structure of which is as follows:
[0128]
[0129] Weigh 1 eq. of the synthesized 3,4-bis(4-hydroxyphenyl)-furan compound and 1 eq. of N-(4-methoxyphenyl)-N-propylethylenesulfonamide compound and place them in a 25 mL single-mouth round-bottom bottle and slowly heat them to 90° C. After reacting for 12 hours, spin-dry the mixture and directly separate and purify it by column chromatography. The eluent ratio was dichloromethane:methanol = 60:1 to obtain a yellow solid with a yield of 59%. 1 H NMR(500MHz,acetone-d6)δ7.38–7.31(m,2H),7.25–7.15(m,4H),6.86(s,4H),6.82–6.77(m,2H),5.55(s,1H),5.35(d,J=1.0Hz, 1H),4.52(q,J=8.6Hz,2H),4.13–4.02(m,2H),3.79(s,3H),3.58(s,1H),2.26–2.17(m,1H),2.13–2.05(m,1H),1.25–1.17(m,3H). 13 C NMR(126MHz,acetone-d6)δ159.67,158.30,157.83,141.04,138.39,132.07,130.61,129.57,128.65,126.26,123.58,115.94,114.95,114. 51,84.55,82.88,68.19,61.80,55.10,30.69,30.32,29.65,29.50,29.35,29.19,29.04,28.88,28.73,20.17,13.84.ESI-HRMS(m / z):[M+Na] +calcd.for C 28 H 29 NO 6 NaS:530.1613; observed,530.1620.
[0130] Embodiment 2:
[0131] This example provides a 5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-N-(3,3,3-trifluoropropyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 23b, the chemical structure of which is as follows:
[0132]
[0133] Referring to the preparation method of Example 1, 1 eq. 3,4-di(4-hydroxyphenyl)-furan compound and 1 eq. N-(4-methoxyphenyl)-N-(3,3,3-trifluoropropyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 62%. 1 HNMR(500MHz,acetone-d6)δ7.34(d,J=8.9Hz,2H),7.19(t,J=8.7Hz,4H),6.85(t,J=9.1Hz,4H),6.78(d,J=8.5Hz,2H),5.52(s,1 H),5.33(d,J=4.4Hz,1H),4.51(q,J=8.6Hz,2H),3.79(s,3H),3.55(dd,J=8.3,4.4Hz,1H),2.22–2.15(m,1H),2.10–2.05(m,3H). 13 CNMR(126MHz,acetone-d6)δ159.67,158.30,157.83,141.04,138.39,132.07,130.61,129.57,128.65,126.26,123.58,115.94,114.95,114. 51,84.55,82.88,68.19,61.80,55.10,30.69,30.32,29.65,29.50,29.35,29.19,29.04,28.88,28.73,20.17,13.84.ESI-HRMS(m / z):[M+Na] + calcd.for C 28 H 26 NO 6 NeF 3 :584.1331; observed,584.1335.
[0134] Embodiment 3:
[0135] This example provides a 5,6-bis(4-hydroxyphenyl)-N-isobutyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 23c, whose chemical structure is as follows:
[0136]
[0137] Referring to the preparation method of Example 1, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. N-isobutyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 55%. 1 H NMR (500 MHz, CDCl 3 )δ7.24(d,J=8.9Hz,2H),7.13(t,J=8.4Hz,4H),6.81(d,J=8.9Hz,2H),6. 75(d,J=7.3Hz,4H),5.54(s,1H),5.47(d,J=2.5Hz,1H),3.79(s,3H),3.5 5(d,J=7.3Hz,2H),3.41(dd,J=8.4,4.4Hz,1H),2.35–2.26(m,1H),2.00– 1.90(m,1H),1.57(dt,J=13.6,6.7Hz,1H),0.91(dd,J=10.5,6.7Hz,6H). 13 C NMR (126MHz, CDCl3) δ159.88,159.11,155.79,137.69,131.74,130.92,129.27,128.87,125.33,125.11,124.41,115.92,11 5.06,114.97,84.62,83.16,77.52,77.26,77.01,67.15,62.60,55.70,33.63,30.75,29.66,28.08.ESI-HRMS(m / z):[M+Na] + calcd.for C 29 H 31 NO 6 SNa:544.1770; observed,544.1763.
[0138] Embodiment 4:
[0139] This example provides a 5,6-bis(4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 23d, the chemical structure of which is as follows:
[0140]
[0141] Referring to the preparation method of Example 1, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. N-isopentyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 45%. 1 H NMR(400MHz, Acetonitrile-d3)δ7.19–7.10(m,6H),6.84–6.72(m,6H),5.40(d,J=1.3Hz,1H),5.26(dd,J=4.4,1.3Hz,1H),3.77(s,3H),3.71–3.63(m,2H) ,3.36(dd,J=8.3,4.5Hz,1H),2.11(s,1H),2.01(dd,J=12.0,8.4Hz,1H),1.5 9(dd,J=13.4,6.7Hz,1H), 1.22(q,J=6.9Hz,2H), 0.83(dd,J=6.7,1.0Hz,6H). 13 C NMR(101MHz, Acetonitrile-d3)δ159.54,157.33,132.16,130.99,129.87,129.04,116.16,115. 93,114.64,85.00,83.25,61.27,55.69,50.15,37.76,30.87,25.44,22.13.HRMS(ESI)m / z[M+Na] + Calculate for C 30 H 33 NO 6 S,535.2029; observed,558.1926.
[0142] Embodiment 5:
[0143] This example provides an N-allyl-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 23e, whose chemical structure is as follows:
[0144]
[0145] Referring to the preparation method of Example 1 above, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. N-allyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 21%. 1HNMR(400MHz, Acetonitrile-d3)δ7.18–7.12(m,6H),6.84–6.79(m,3H),6.79–6.72(m,3H),5.75(d,J=6.6Hz,1H),5.42(d,J=1.2Hz,1H),5.28(dd,J=4.3, 1.3Hz,1H),5.12–4.98(m,2H),4.27(dt,J=6.2,1.4Hz,2H),3.76(s,3H),3.4 0(dd,J=8.4,4.5Hz,1H),2.12(d,J=4.3Hz,1H),2.02(dd,J=12.0,8.4Hz,1H). 13 C NMR(101MHz, Acetonitrile-d3)δ159.57,157.51,138.05,134.59,131.22,129.83,129.08,11 8.37,116.15,115.94,114.58,84.98,83.28,61.84,55.68,54.79,30.87.HRMS(ESI)m / z[M+Na] + Calculate for C 28 H 27 NO 6 S,505.1559;found,528.1451.
[0146] Embodiment 6:
[0147] This example provides N-(2-hydroxyethyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 23f, whose chemical structure is as follows:
[0148]
[0149] Referring to the preparation method of Example 1, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. N-(2-hydroxyethyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 69%.
[0150] Embodiment 7:
[0151] This example provides 23 g of N-(2-fluoro-2-methylpropyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide, the chemical structure of which is as follows:
[0152]
[0153] Referring to the preparation method of Example 1, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. N-(2-fluoro-2-methylpropyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 66%.
[0154] Embodiment 8:
[0155] This embodiment provides N-(cyclopropylmethyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 23h, whose chemical structure is as follows:
[0156]
[0157] Referring to the preparation method of Example 1 above, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. N-(cyclopropylmethyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 32%. 1 H NMR(400MHz, Acetonitrile-d3)δ7.12–7.09(m,4H),7.05–7.01(m,2H),6.83–6.77(m,2H),6.75–6.68(m,4H),5.39(d,J=1 .2Hz,1H),5.27(dd,J=4.5,1.3Hz,1H),3.74(s,3H),3.30(dd,J=8.5,4.5Hz,1H),2.20(t,J=4.5Hz,1H),1.99–1.96(m,1H). 13 C NMR(101MHz, Acetonitrile-d3)δ159.64,149.85,132.84,131.54,129.88,129.04,116.16,115 .93,114.60,85.00,83.27,61.80,57.14,55.69,30.84,11.05,3.79,3.72.HRMS(ESI)m / z[M+Na] + Calculate for C 29 H 29 NO 6 S,519.1716; observed,542.1612.
[0158] Embodiment 9:
[0159] This example provides N-(cyclobutylmethyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 23i, whose chemical structure is as follows:
[0160]
[0161] Referring to the preparation method of Example 1 above, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. N-(cyclobutylmethyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 48%. 1 H NMR(400MHz, Acetonitrile-d3)δ7.13(qd,J=6.4,2.1Hz,6H),6.89–6.66(m,6H),5.4 1(d,J=1.3Hz,1H),5.27(dd,J=4.4,1.3Hz,1H),3.77(s,3H),3.66(d,J=7.5Hz,2H),3. 36(dd,J=8.3,4.5Hz,1H),2.28–2.20(m,1H),2.12(d,J=4.4Hz,1H),2.01(dd,J=12.0, 8.4Hz,1H),1.90–1.82(m,2H),1.80–1.74(m,2H),1.63(ddd,J=11.0,6.9,2.8Hz,2H). 13 C NMR(151MHz, Acetonitrile-d3)δ159.02,156.75,141.02,137.51,130.50,128.46,115.60,115. 36,114.01,84.42,82.67,60.80,56.49,55.12,34.22,30.28,25.38,17.74.HRMS(ESI)m / z[M+Na] + Calculate for C 30 H 31 NO 6 S,533.1872; observed,556.1765.
[0162] Embodiment 10:
[0163] This example provides an N-cyclohexyl-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 23j, whose chemical structure is as follows:
[0164]
[0165] Referring to the preparation method of Example 1, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. N-cyclohexyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 45%.
[0166] Embodiment 11:
[0167] This embodiment provides a 5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-N-phenyl-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 23k, whose chemical structure is as follows:
[0168]
[0169] Referring to the preparation method of Example 1, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. N-(4-methoxyphenyl)-N-phenylethanesulfonamide were used as raw materials to obtain a yellow solid with a yield of 51%. 1 H NMR(400MHz, Acetonitrile-d3)δ7.43–7.38(m,2H),7.37–7.31(m,4H),7.29–7.24(m,1H),7.18–7.09(m,4H),6.90–6.84(m,2H),6.80–6.72( m,4H),5.46(d,J=1.3Hz,1H),5.29(dd,J=4.3,1.3Hz,1H),3.76(s,3H),3.64(dd,J=8.3,4.6Hz,1H),2.25–2.22(m,1H),2.10(d,J=2.6Hz,1H). 13 C NMR(101MHz, Acetonitrile-d3)δ157.53,157.39,142.75,137.90,134.61,131.18,129.97,129.80 ,129.10,128.83,127.92,115.94,115.09,85.25,83.29,63.23,55.75,31.18.HRMS(ESI)m / z[M+Na] + Calculate for C 31 H 27 NO 6 S,541.1559; observed,564.1458.
[0170] Embodiment 12:
[0171] This example provides an N-benzyl-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 231, whose chemical structure is as follows:
[0172]
[0173] Referring to the preparation method of Example 1, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. N-benzyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 43%. 1 H NMR(400MHz, Acetonitrile-d3)δ7.26–7.21(m,4H),7.15(dd,J=8.8,3.2Hz,4H) ,7.10(d,J=8.7Hz,3H),6.81–6.77(m,2H),6.73(dd,J=10.6,7.9Hz,4H),5.47(d, J=1.3Hz,1H),5.31(d,J=4.3Hz,1H),4.86(d,J=3.3Hz,2H),3.71(s,3H),3.47(d d,J=8.3,4.5Hz,1H),2.20(dd,J=12.0,4.5Hz,1H),2.06(dd,J=12.1,8.4Hz,1H). 13 C NMR(151MHz, Acetonitrile-d3)δ163.36,157.25,130.51,130.01,129.80,129.31,128.51,128.38,12 8.35,127.54,115.62,115.38,113.91,80.51,78.95,56.24,55.13,55.05,26.77.HRMS(ESI)m / z[M+Na] + calcdfor C 32 H 29 NO 6 S,555.1716; observed,578.1635.
[0174] Embodiment 13:
[0175] This embodiment provides a 4,4'-(5-(indolyl-1-ylsulfonyl)-7-oxabicyclo[2.2.1]hept-2-ene-2,3-diyl)diphenol 23m, whose chemical structure is as follows:
[0176]
[0177] Referring to the preparation method of Example 1, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. 1-ethylenesulfonyl indoline were used as raw materials to obtain a yellow solid with a yield of 56%. 1 H NMR (400MHz, Acetone-d6) δ8.63(d,J=1.2Hz,2H),7.46(d,J=8.0Hz,1H),7.24(d,J=7 .4Hz,1H),7.20–7.13(m,3H),7.04–6.98(m,3H),6.81–6.70(m,4H),5.48(d,J=1.2Hz ,1H),5.31(dd,J=4.4,1.1Hz,1H),4.14–4.07(m,2H),3.67(dd,J=8.4,4.4Hz,1H),3. 12(td,J=8.2,5.0Hz,2H), 2.40(dt,J=11.9,4.5Hz,1H), 2.01(dd,J=11.9,8.4Hz,1H). 13 C NMR (101MHz, Acetone-d6) δ170.19,157.36,157.23,142.62,140.91,137.12,132.00,128.85,128.45,127.53,125.56,1 24.19,123.62,123.33,115.57,115.51,113.83,84.29,82.79,61.19,59.75,50.34,30.12,27.84,20.02,17.98,13.66.
[0178] Embodiment 14:
[0179] This embodiment provides a 4,4'-(5-((6-methoxy-3,4-dihydroquinolin-1(2H)-yl)sulfonyl)-7-oxabicyclo[2.2.1]hept-2-ene-2,3-diyl)diphenol 23n, whose chemical structure is as follows:
[0180]
[0181] Referring to the preparation method of Example 1, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. 6-methoxy-1-(vinylsulfonyl)-1,2,3,4-tetrahydroquinoline were used as raw materials to obtain a yellow solid with a yield of 45%. 1H NMR(400MHz, Acetone-d6)δ8.67(d,J=16.8Hz,2H),7.64(d,J=9.0Hz,1H),7.20–7.12(m,2H), 7.06–6.97(m,2H),6.80–6.72(m,5H),6.69(d,J=3.0Hz,1H),5.34–5.24(m,2H),3.85–3.78(m, 1H),3.77(s,3H),3.76–3.68(m,1H),3.57(dd,J=8.4,4.5Hz,1H),2.71(dtd,J=23.3,16.8,6. 7Hz,2H),2.28(dt,J=11.8,4.4Hz,1H),2.03–1.97(m,1H),1.89(dtd,J=13.9,7.0,4.8Hz,2H). 13 C NMR (101MHz, Acetone-d6) δ157.31,157.30,156.57,140.97,137.27,131.59,130.42,128.78,128.63,124.35,1 24.28,123.62,115.58,115.47,114.03,112.24,84.55,82.55,61.94,54.78,54.73,46.50,30.38,26.80,22.45.
[0182] Embodiment 15:
[0183] This embodiment provides a 4,4'-(5-((3,4-dihydroquinolin-1(2H)-yl)sulfonyl)-7-oxabicyclo[2.2.1]hept-2-ene-2,3-diyl)diphenol 23o, whose chemical structure is as follows:
[0184]
[0185] Referring to the preparation method of Example 1, 1 eq. 3,4-di(4-hydroxyphenyl)-furan and 1 eq. 1-(vinylsulfonyl)-1,2,3,4-tetrahydroquinoline were used as raw materials to obtain a yellow solid with a yield of 53%. 1H NMR(400MHz, Acetone-d6)δ8.61(s,1H),8.58(s,1H),7.64(d,J=8.3Hz,1H),7.19–7.13(m,2H),7.0 5–6.97(m,2H),6.94(dd,J=11.2,2.4Hz,2H),6.78(q,J=2.5Hz,2H),6.75(q,J=2.5Hz,2H),5.32(d, J=1.2Hz,1H),5.29(dd,J=4.4,1.1Hz,1H),3.86–3.70(m,2H),3.61(dd,J=8.3,4.5Hz,1H),2.81–2. 61(m,2H),2.31(dt,J=11.8,4.5Hz,1H),2.00(dd,J=11.9,8.4Hz,1H),1.89(pd,J=7.1,4.6Hz,2H). 13 C NMR (101MHz, Acetone-d6) δ157.30,157.27,141.00,137.27,134.97,133.51,130.16,129.55,129.51,128.71,128.68,1 27.12,124.27,123.63,122.33,115.56,115.50,84.49,82.60,61.97,59.75,46.66,30.31,26.71,22.55,19.87,13.67.
[0186] Embodiment 16:
[0187] This embodiment provides a 5,6-bis(3-fluoro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24a, whose chemical structure is as follows:
[0188]
[0189] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(2-fluorophenol) and 1 eq. N-isopentyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 43%. 1H NMR(500MHz,Chloroform-d)δ7.25(dd,J=7.9,1.9Hz,1H),7.13(dd,J=8.2,2.2Hz,3H),7.05(ddd,J=10.2,7.5,2 .2Hz,2H),6.90–6.80(m,4H),6.50(s,2H),5.36(td,J=4.2,1.1Hz,1H),4.89(dd,J=6.7,1.0Hz,1H),3.79(s,3H) ,3.77(dt,J=13.2,9.2Hz,1H),3.57(dt,J=13.3,9.3Hz,1H),3.45(td,J=8.0,6.7Hz,1H),2.55(ddd,J=12.2,7.9 ,4.2Hz,1H),2.43(ddd,J=12.4,8.0,4.2Hz,1H),1.78–1.53(m,3H),0.92(d,J=6.7Hz,3H),0.87(d,J=6.7Hz,3H). 13 C NMR(125MHz,Chloroform-d)δ153.71,151.24,151.20,149.22,149.18,146.23,146.20,146.07 ,146.05,141.83,141.81,138.38,138.35,135.04,128.24,128.18,126.80,126.73,124.76,123 .21,123.19,123.11,123.08,116.46,116.44,116.40,116.37,115.85,115.56,115.40,115.12, 114.96,87.15,84.28,63.18,55.32,53.02,37.48,31.92,27.45,22.81.ESI-HRMS(m / z):[M+Na] + calcd.for C 30 H 31 F 2 NO 6 S:594.1840; observed,594.1335.
[0190] Embodiment 17:
[0191] This example provides an N-(cyclopropylmethyl)-5,6-bis(3-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24b, whose chemical structure is as follows:
[0192]
[0193] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(2-fluorophenol) and 1 eq. N-(cyclopropylmethyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 33%. 1 H NMR(500MHz,Chloroform-d)δ9.95(s,2H),7.39–7.31(m,4H),7.30(dd,J=5.6,2.0Hz,2H),6.92(dd,J=7.5,1.7Hz,4H),5.13(d,J=1.1Hz,1H),4. 64(d,J=0.9Hz,1H),4.58(s,1H),3.92(s,2H),3.80(s,3H),2.82(s,1H) ,2.77(s,1H),1.94(s,1H),1.35(d,J=4.9Hz,2H),1.22(d,J=5.1Hz,2H). 13 C NMR(125MHz,Chloroform-d)δ153.70,151.24,151.20,149.22,149.18,146.23,146.20,146. 07,146.05,141.83,141.81,138.38,138.35,135.01,128.24,128.18,126.80,126.73,124.85 ,123.21,123.19,123.11,123.08,116.46,116.44,116.40,116.37,115.84,115.56,115.40,1 15.12,114.96,87.15,84.28,63.22,56.61,55.32,31.92,9.27,5.48.ESI-HRMS(m / z):[M+Na] + calcd.for C 29 H 27 F 2 NO 6 SN:578.1527; observed,578.1335.
[0194] Embodiment 18:
[0195] This example provides an N-(cyclobutylmethyl)-5,6-bis(3-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24c, whose chemical structure is as follows:
[0196]
[0197] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(2-fluorophenol) and 1 eq. N-(cyclobutylmethyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 38%. 1 H NMR(500MHz,Chloroform-d)δ7.25(dd,J=7.9,1.9Hz,1H),7.16–7.09(m,3H),7.05(ddd,J=10.2,7.5,2.2Hz, 2H),6.90–6.80(m,4H),6.50(s,2H),5.36(td,J=4.2,1.1Hz,1H),4.89(dd,J=6.7,1.0Hz,1H),3.79(s,2H),3. 75(dd,J=12.5,5.4Hz,1H),3.53(dd,J=12.5,5.3Hz,1H),3.46(td,J=7.9,6.7Hz,1H),2.55(ddd,J=12.2,7.9 ,4.2Hz,1H),2.43(ddd,J=12.4,8.0,4.2Hz,1H),2.23(p,J=5.4Hz,1H),1.86–1.70(m,4H),1.69–1.56(m,2H). 13 CNMR(125MHz,Chloroform-d)δ153.70,151.24,151.20,149.22,149.18,146.23,146.20,146.07 ,146.05,141.83,141.81,138.38,138.35,135.09,128.24,128.18,126.80,126.73,124.85,123 .21,123.19,123.11,123.08,116.46,116.44,116.40,116.37,115.84,115.56,115.40,115.12, 114.96,87.15,84.28,63.22,55.32,55.30,32.76,31.92,29.96,20.19.ESI-HRMS(m / z):[M+Na] + calcd.for C 30 H 29 F 2 NO 6 S:592.1684; observed,592.1335.
[0198] Embodiment 19:
[0199] This embodiment provides an N-cyclohexyl-5,6-bis(3-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24d, whose chemical structure is as follows:
[0200]
[0201] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(2-fluorophenol) and 1 eq. N-cyclohexyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 45%. 1 H NMR(500MHz,Chloroform-d)δ7.25(dd,J=7.9,1.9Hz,1H),7.16–7.01(m,5H),6.86(dd,J =10.1,5.0Hz,2H),6.83–6.79(m,2H),6.50(s,2H),5.36(td,J=4.2,1.1Hz,1H),4.92(dd ,J=6.9,1.1Hz,1H),3.86(p,J=7.1Hz,1H),3.79(s,3H),3.46(td,J=7.7,6.9Hz,1H),2.5 5(ddd,J=12.1,7.7,4.2Hz,1H),2.49–2.40(m,1H),1.95–1.81(m,4H),1.62–1.34(m,6H). 13 CNMR(125MHz,Chloroform-d)δ153.64,151.24,151.20,149.22,149.18,146.23,146.20,146.07 ,146.05,141.83,141.81,138.38,138.36,133.90,128.24,128.18,126.80,126.73,124.29,123 .21,123.19,123.11,123.08,116.46,116.44,116.40,116.37,115.56,115.48,115.40,115.12, 114.96,87.18,84.28,64.16,62.27,55.32,31.94,31.28,26.26,24.47.ESI-HRMS(m / z):[M+Na] + calcd.for C 31 H 31 F 2 NO 6S:603.1840; observed,603.1335.
[0202] Embodiment 20:
[0203] This embodiment provides a 5,6-bis(3-chloro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24e, whose chemical structure is as follows:
[0204]
[0205] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(2-chlorophenol) and 1 eq. N-isopentyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 63%. 1 H NMR(500MHz,Chloroform-d)δ7.51(d,J=1.9Hz,1H),7.41(d,J=2.2Hz,1H),7.18(ddd,J=9.0,3.0,2.0Hz,2H),7.16–7.1 1(m,2H),6.89(d,J=9.0Hz,2H),6.86–6.80(m,2H),6.48(s,2H),5.36(td,J=4.2,1.1Hz,1H),4.88(dd,J=6.7,1.0Hz,1H ),3.79(s,3H),3.77(dt,J=13.3,9.3Hz,1H),3.57(dt,J=13.3,9.3Hz,1H),3.45(td,J=8.0,6.7Hz,1H),2.55(ddd,J=12 .2,7.9,4.2Hz,1H),2.43(ddd,J=12.4,8.0,4.2Hz,1H),1.78–1.53(m,3H),0.92(d,J=6.7Hz,3H),0.87(d,J=6.7Hz,3H). 13 C NMR(125MHz,Chloroform-d)δ155.08,155.02,153.71,140.73,137.42,135.04,129.07,128.78,127.54,126.17,126.11,124.76,120.3 8,120.35,116.50,116.47,115.85,86.87,83.97,63.17,55.32,53.02,37.48,31.92,27.45,22.81.ESI-HRMS(m / z):[M+Na]+calcd.for C 30 H31 Cl 2 NO 6 S:626.1249; observed,626.1233.
[0206] Embodiment 21:
[0207] This embodiment provides a 5,6-bis(3-chloro-4-hydroxyphenyl)-N-(cyclopropylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24f, whose chemical structure is as follows:
[0208]
[0209] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(2-chlorophenol) and 1 eq. N-(cyclopropylmethyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 43%. 1 H NMR(500MHz,Chloroform-d)δ7.51(d,J=1.9Hz,1H),7.41(d,J=2.2Hz,1H),7.18(ddd,J=9.0,3.0,2.0Hz,2H) ,7.12(s,1H),7.15–7.09(m,0H),6.89(d,J=9.0Hz,2H),6.86–6.80(m,2H),6.48(s,2H),5.36(td,J=4.2,1.1H z,1H),4.88(dd,J=6.7,1.0Hz,1H),3.79(s,2H),3.63(dd,J=12.3,5.5Hz,1H),3.51–3.41(m,2H),2.55(ddd, J=12.2,7.9,4.2Hz,1H),2.43(ddd,J=12.4,8.0,4.2Hz,1H),1.35(dq,J=11.6,5.8Hz,1H),0.45–0.35(m,4H). 13 CNMR(125MHz,Chloroform-d)δ155.08,155.02,153.70,140.73,137.42,135.01,129.07,128.78,127.54,126.17,126.11,12 4.85,120.38,120.35,116.50,116.47,115.84,86.87,83.97,63.22,56.61,55.32,31.92,9.27,5.48.ESI-HRMS(m / z):[M+Na] + calcd.forC29 H 27 Cl 2 NO 6 S: 610.0936; observed, 610.0436.
[0210] Embodiment 22:
[0211] This embodiment provides 24 g of 5,6-bis(3-chloro-4-hydroxyphenyl)-N-(cyclobutylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide, and its chemical structure is as follows:
[0212]
[0213] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(2-chlorophenol) and 1 eq. N-(cyclobutylmethyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 36%. 1 H NMR(500MHz,Chloroform-d)δ7.51(d,J=1.9Hz,1H),7.41(d,J=2.2Hz,1H),7.18(ddd,J=9.0,3.0,2.0Hz,2H),7.12(s, 1H),7.15–7.09(m,0H),6.91–6.80(m,3H),6.48(s,2H),5.36(td,J=4.2,1.1Hz,1H),4.88(dd,J=6.7,1.0Hz,1H),3.79 (s,2H),3.75(dd,J=12.5,5.4Hz,1H),3.53(dd,J=12.5,5.3Hz,1H),3.46(td,J=7.9,6.7Hz,1H),2.55(ddd,J=12.2,7. 9,4.2Hz,1H),2.43(ddd,J=12.4,8.0,4.2Hz,1H),2.23(dt,J=10.7,5.4Hz,1H),1.86–1.70(m,4H),1.69–1.56(m,2H). 13C NMR(125MHz,Chloroform-d)δ155.08,155.02,153.70,140.73,137.42,135.09,129.07,128.78,127.54,126.17,126.11,124.85,120.3 8,120.35,116.50,116.47,115.84,86.87,83.97,63.22,55.32,55.30,32.76,31.92,29.96,20.19.ESI-HRMS(m / z):[M+Na]+calcd.for C 30 H 29 Cl 2 NO 6 S:624.1093; observed,624.1066.
[0214] Embodiment 23:
[0215] This embodiment provides a 5,6-bis(3-chloro-4-hydroxyphenyl)-N-cyclohexyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24h, whose chemical structure is as follows:
[0216]
[0217] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(2-chlorophenol) and 1 eq. N-cyclohexyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 35%. 1 H NMR(500MHz,Chloroform-d)δ7.51(d,J=1.9Hz,1H),7.41(d,J=2.2Hz,1H),7.18(ddd,J=9.0,3.0,2 .0Hz,2H),7.13–7.07(m,2H),6.89(d,J=9.0Hz,2H),6.85–6.79(m,2H),6.48(s,2H),5.36(td,J=4.2 ,1.1Hz,1H),4.92(dd,J=6.9,0.9Hz,1H),3.86(p,J=7.1Hz,1H),3.79(s,2H),3.46(td,J=7.7,6.9H z,1H),2.55(ddd,J=12.0,7.7,4.3Hz,1H),2.49–2.40(m,1H),1.95–1.81(m,4H),1.62–1.34(m,6H). 13C NMR(125MHz,Chloroform-d)δ155.08,155.02,153.64,140.73,137.42,133.90,129.07,128.78,127.54,126.17,126.11,124.29, 120.38,120.35,116.50,116.47,115.48,86.90,83.97,64.17,62.27,55.32,31.94,31.28,26.26,24.47.ESI-HRMS(m / z):[M+Na] + calcd.for C 31 H 31 Cl 2 NO 6 S:638.1249; observed,638.1149.
[0218] Embodiment 24:
[0219] This embodiment provides a 5,6-bis(2-fluoro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24i, whose chemical structure is as follows:
[0220]
[0221] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(3-fluorophenol) and 1 eq. N-isopentyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 54%. 1 HNMR(500MHz,Chloroform-d)δ9.32(s,2H),7.24(ddd,J=12.0,8.7,5.0Hz,2H),7.17–7.11(m,2H),6.86–6. 80(m,2H),6.65–6.57(m,4H),5.00(dd,J=6.7,1.0Hz,1H),4.71(td,J=4.1,1.0Hz,1H),3.79(s,3H),3.77(dt ,J=13.3,9.3Hz,1H),3.57(dt,J=13.3,9.3Hz,1H),3.47(td,J=8.0,6.7Hz,1H),2.59(ddd,J=12.1,7.9,4.1 Hz,1H),2.46(ddd,J=12.3,8.0,4.2Hz,1H),1.78–1.53(m,3H),0.92(d,J=6.7Hz,3H),0.87(d,J=6.7Hz,3H).13 C NMR(125MHz,Chloroform-d)δ162.23,162.06,160.21,160.04,159.45,159.42,159.39,159.35,153.71,13 9.22,139.20,139.16,139.13,136.96,136.93,136.90,136.87,135.04,129.88,129.81,129.76,129.70,12 4.76,115.85,114.39,114.23,111.69,111.68,111.66,111.65,110.95,110.79,104.59,104.56,104.43,10 4.40,85.19,85.16,82.52,82.49,63.20,55.32,53.02,37.48,32.03,27.45,22.81.ESI-HRMS(m / z):[M+Na] + calcd.forC 30 H 31 F 2 NO 6 S:594.1840; observed,594.1436.
[0222] Embodiment 25:
[0223] This example provides an N-(cyclopropylmethyl)-5,6-bis(2-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24j, whose chemical structure is as follows:
[0224]
[0225] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(3-fluorophenol) and 1 eq. N-(cyclopropylmethyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 52%. 1H NMR(500MHz,Chloroform-d)δ9.32(s,2H),7.24(ddd,J=12.0,8.7,5.0Hz,2H),7.15–7.09(m, 2H),6.86–6.80(m,2H),6.65–6.57(m,4H),5.00(dd,J=6.7,1.0Hz,1H),4.71(td,J=4.1,1.0Hz ,1H),3.79(s,2H),3.63(dd,J=12.3,5.5Hz,1H),3.52–3.41(m,2H),2.59(ddd,J=12.1,7.9,4. 1Hz, 1H), 2.46 (ddd, J=12.3, 8.0, 4.2Hz, 1H), 1.35 (dq, J=11.6, 5.8Hz, 1H), 0.45–0.35 (m, 4H). 13 C NMR(125MHz,Chloroform-d)δ162.23,162.06,160.21,160.04,159.45,159.42,159.39,159.35,153.70, 139.22,139.20,139.16,139.13,136.96,136.93,136.89,136.87,135.01,129.88,129.81,129.76,129.7 0,124.85,115.84,114.39,114.23,111.69,111.68,111.66,111.65,110.95,110.79,104.59,104.56,104 .43,104.40,85.19,85.16,82.52,82.49,63.24,56.61,55.32,32.03,9.27,5.48.ESI-HRMS(m / z):[M+Na] + calcd.for C 29 H 27 F 2 NO 6 S:578.1527; observed,578.1335.
[0226] Embodiment 26:
[0227] This embodiment provides an N-(cyclobutylmethyl)-5,6-bis(2-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24k, whose chemical structure is as follows:
[0228]
[0229] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(3-fluorophenol) and 1 eq. N-(cyclobutylmethyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 32%. 1 H NMR(500MHz,Chloroform-d)δ9.32(s,2H),7.24(ddd,J=12.0,8.7,5.0Hz,2H),7.15–7.09(m,2H) ,6.86–6.80(m,2H),6.65–6.57(m,4H),5.00(dd,J=6.7,1.0Hz,1H),4.71(td,J=4.1,1.0Hz,1H), 3.79(s,2H),3.75(dd,J=12.5,5.4Hz,1H),3.56–3.43(m,2H),2.59(ddd,J=12.1,7.9,4.1Hz,1H) ,2.46(ddd,J=12.3,8.0,4.2Hz,1H),2.23(p,J=5.4Hz,1H),1.86–1.70(m,4H),1.69–1.56(m,2H). 13 C NMR(125MHz,Chloroform-d)δ162.23,162.06,160.21,160.04,159.45,159.42,159.39,159.35,153.70,13 9.22,139.20,139.16,139.13,136.96,136.93,136.89,136.87,135.09,129.88,129.81,129.76,129.70,12 4.85,115.84,114.39,114.23,111.69,111.68,111.66,111.65,110.95,110.79,104.59,104.56,104.43,10 4.40,85.19,85.16,82.52,82.49,63.24,55.32,55.30,32.76,32.03,29.96,20.19.ESI-HRMS(m / z):[M+Na] + calcd.for C 30 H 29 F 2 NO 6 S:592.1684; observed,592.1436.
[0230] Embodiment 27:
[0231] This embodiment provides an N-cyclohexyl-5,6-bis(2-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 241, whose chemical structure is as follows:
[0232]
[0233] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(3-fluorophenol) and 1 eq. N-cyclohexyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 46%. 1 H NMR (500MHz, Chloroform-d) δ9.32 (s, 2H), 7.24 (ddd, J = 12.0, 8.7, 5.1Hz, 2H), 7.13–7. 07(m,2H),6.85–6.79(m,2H),6.65–6.57(m,4H),5.03(dd,J=6.9,1.1Hz,1H),4.71(td,J =4.1,1.0Hz,1H),3.86(p,J=7.1Hz,1H),3.79(s,2H),3.47(td,J=7.7,6.9Hz,1H),2.58 (ddd,J=12.1,7.7,4.2Hz,1H),2.52–2.43(m,1H),1.95–1.81(m,4H),1.62–1.34(m,5H). 13 CNMR(125MHz,Chloroform-d)δ162.23,162.06,160.21,160.04,159.45,159.42,159.39,159.35,153.64,13 9.22,139.20,139.16,139.13,136.96,136.93,136.90,136.87,133.92,129.88,129.81,129.76,129.70,12 4.29,115.48,114.39,114.23,111.69,111.68,111.66,111.65,110.95,110.79,104.59,104.56,104.43,10 4.40,85.26,85.23,82.52,82.49,64.22,62.27,55.32,32.05,31.28,26.26,24.47.ESI-HRMS(m / z):[M+Na] + calcd.forC 31 H 31 F 2 NO 6S:606.1840; observed,606.1335.
[0234] Embodiment 28:
[0235] This embodiment provides a 5,6-bis(2-chloro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24m, whose chemical structure is as follows:
[0236]
[0237] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(3-chlorophenol) and 1 eq. N-isopentyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 59%. 1 H NMR(500MHz,Chloroform-d)δ7.82(s,2H),7.20(d,J=9.3Hz,1H),7.16(d,J=9.2Hz,1H),7.17–7.11(m,2H),6.99(d,J= 2.3Hz,2H),6.86–6.80(m,2H),6.65(dd,J=9.3,2.2Hz,2H),5.00(dd,J=6.7,1.0Hz,1H),4.65(td,J=4.2,0.9Hz,1H),3 .79(s,3H),3.77(dt,J=13.3,9.3Hz,1H),3.57(dt,J=13.3,9.3Hz,1H),3.47(td,J=8.0,6.7Hz,1H),2.59(ddd,J=12.2 ,7.9,4.2Hz,1H),2.46(ddd,J=12.3,8.0,4.2Hz,1H),1.78–1.53(m,3H),0.92(d,J=6.7Hz,3H),0.87(d,J=6.7Hz,3H). 13 C NMR(125MHz,Chloroform-d)δ157.61,157.59,153.71,139.98,138.01,135.04,133.35,133.34,128.80,128.64,128.56,127.25,124.7 6,116.95,116.94,115.85,115.10,85.06,82.42,63.20,55.32,53.02,37.48,31.92,27.45,22.81.ESI-HRMS(m / z):[M+Na]+calcd.for C 30 H31 Cl 2 NO 6 S:626.1249; observed,626.1049.
[0238] Embodiment 29:
[0239] This embodiment provides a 5,6-bis(2-chloro-4-hydroxyphenyl)-N-(cyclopropylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24n, whose chemical structure is as follows:
[0240]
[0241] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(3-chlorophenol) and 1 eq. N-(cyclopropylmethyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 38%. 1 H NMR(500MHz,Chloroform-d)δ7.82(s,2H),7.22–7.09(m,4H),6.99(d,J=2.3Hz,2H),6.86–6 .80(m,2H),6.65(dd,J=9.3,2.2Hz,2H),5.00(dd,J=6.7,1.0Hz,1H),4.65(td,J=4.2,0.9Hz ,1H),3.79(s,2H),3.63(dd,J=12.3,5.5Hz,1H),3.52–3.41(m,2H),2.59(ddd,J=12.2,7.9, 4.2Hz, 1H), 2.46 (ddd, J=12.3, 8.0, 4.2Hz, 1H), 1.35 (hept, J=5.8Hz, 1H), 0.45–0.35 (m, 4H). 13 C NMR(125MHz,Chloroform-d)δ157.61,157.59,153.70,139.98,138.01,135.01,133.35,133.34,128.80,128.64,128.56,127.25,1 24.85,116.95,116.94,115.84,115.10,85.06,82.42,63.24,56.61,55.32,31.92,9.27,5.48.ESI-HRMS(m / z):[M+Na]+calcd.for C 29 H 27 Cl 2 NO 6S:610.0936; observed,610.0436.
[0242] Embodiment 30:
[0243] This embodiment provides a 5,6-bis(2-chloro-4-hydroxyphenyl)-N-(cyclobutylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24o, whose chemical structure is as follows:
[0244]
[0245] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(3-chlorophenol) and 1 eq. N-(cyclobutylmethyl)-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 42%. 1 H NMR(500MHz,Chloroform-d)δ7.82(s,2H),7.18(dd,J=17.3,9.3Hz,2H),7.14–7.09(m,2H),6.99(d,J= 2.3Hz,2H),6.86–6.80(m,2H),6.65(dd,J=9.3,2.2Hz,2H),5.00(dd,J=6.7,1.0Hz,1H),4.65(td,J=4.2 ,0.9Hz,1H),3.79(s,2H),3.75(dd,J=12.5,5.4Hz,1H),3.56–3.43(m,2H),2.59(ddd,J=12.2,7.9,4.2H z,1H),2.46(ddd,J=12.3,8.0,4.2Hz,1H),2.23(p,J=5.4Hz,1H),1.86–1.70(m,4H),1.69–1.56(m,2H). 13 C NMR(125MHz,Chloroform-d)δ157.61,157.59,153.70,139.98,138.01,135.09,133.35,133.34,128.80,128.64,128.56,127.25,124.8 5,116.95,116.94,115.84,115.10,85.06,82.42,63.24,55.32,55.30,32.76,31.92,29.96,20.19.ESI-HRMS(m / z):[M+Na]+calcd.forC 30 H 29 Cl 2 NO 6S:624.1093; observed,624.1436.
[0246] Embodiment 31:
[0247] This embodiment provides a 5,6-bis(2-chloro-4-hydroxyphenyl)-N-cyclohexyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide 24p, whose chemical structure is as follows:
[0248]
[0249] Referring to the preparation method of Example 1, 1 eq. 4,4'-(furan-3,4-diyl)bis(3-chlorophenol) and 1 eq. N-cyclohexyl-N-(4-methoxyphenyl)ethylenesulfonamide were used as raw materials to obtain a yellow solid with a yield of 51%. 1 H NMR(500MHz,Chloroform-d)δ7.82(s,2H),7.18(dd,J=17.3,9.2Hz,2H),7.13–7.07(m,2H),6.99 (d,J=2.3Hz,2H),6.85–6.79(m,2H),6.65(dd,J=9.3,2.2Hz,2H),4.97(dd,J=6.9,1.1Hz,1H),4.6 5(td,J=4.2,0.9Hz,1H),3.86(p,J=7.1Hz,1H),3.79(s,2H),3.47(td,J=7.7,6.9Hz,1H),2.58(dd d,J=12.1,7.7,4.2Hz,1H),2.52–2.43(m,1H),1.95–1.81(m,4H),1.62–1.34(m,5H),1.44(s,0H). 13 C NMR(125MHz,Chloroform-d)δ157.61,157.59,153.64,139.98,138.01,133.92,133.35,133.34,128.80,128.64,128.56,127.25,124.2 9,116.95,116.94,115.48,115.10,85.10,82.42,64.25,62.27,55.32,32.06,31.28,26.26,24.47.ESI-HRMS(m / z):[M+Na]+calcd.for C 31 H 31 Cl 2 NO 6 S:638.1249; observed,638.1436.
[0250] Embodiment 32:
[0251] This example investigates the anti-drug resistant mutant breast cancer activity of the oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents obtained in Examples 1 to 31 above. The affinity (Relative Binding Affinity, RBA) of the target compounds obtained in the above examples to ER, as well as the inhibitory activity (IC50, unit mM) to wild-type MCF-7 and three drug resistant mutant breast cancer cells MCF-7Y537S, MCF-7D538G were measured, and the results are shown in Table 1.
[0252] Table 1:
[0253]
[0254]
[0255] From the results in Table 1, it can be seen that the oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents prepared by the present invention showed certain inhibitory activity against wild-type breast cancer cells MCF-7 and three drug-resistant mutant breast cancer cells MCF-7Y537S, MCF-7D538G, and MCF-7EGFR; and the oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing fluorine atoms or chlorine atoms substituted on the benzene ring further enhanced the affinity for estrogen receptors and interfered with the dimerization interface of estrogen receptors.
[0256] The above examples are merely illustrative of the present invention and do not constitute a limitation on the protection scope of the present invention. All designs that are the same or similar to the present invention fall within the protection scope of the present invention.
Claims
1. Oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents, characterized in that: It has the following general structure: wherein X is selected from -H, -F or -Cl; R2 is selected from R1 is selected from 2. The oxygen-bridged bicyclo-[2.2.1]-heptene compound containing different sulfonamide nitrogen atom substituents as claimed in claim 1, characterized in that: Any one of the following compounds: 5,6-Bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-N-propyl-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-N-(3,3,3-trifluoropropyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(4-hydroxyphenyl)-N-isobutyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-allyl-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-(2-Hydroxyethyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-(2-Fluoro-2-methylpropyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-(Cyclopropylmethyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-(Cyclobutylmethyl)-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-cyclohexyl-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-N-phenyl-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-Benzyl-5,6-bis(4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 4,4'-(5-(indolin-1-ylsulfonyl)-7-oxabicyclo[2.2.1]hept-2-ene-2,3-diyl)diphenol; 4,4'-(5-((6-methoxy-3,4-dihydroquinolin-1(2H)-yl)sulfonyl)-7-oxabicyclo[2.2.1]hept-2-ene-2,3-diyl)diphenol; 4,4'-(5-((3,4-dihydroquinolin-1(2H)-yl)sulfonyl)-7-oxabicyclo[2.2.1]hept-2-ene-2,3-diyl)diphenol; 5,6-Bis(3-fluoro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-(Cyclopropylmethyl)-5,6-bis(3-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-(Cyclobutylmethyl)-5,6-bis(3-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-cyclohexyl-5,6-bis(3-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(3-chloro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(3-chloro-4-hydroxyphenyl)-N-(cyclopropylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(3-chloro-4-hydroxyphenyl)-N-(cyclobutylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(3-chloro-4-hydroxyphenyl)-N-cyclohexyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(2-fluoro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-(Cyclopropylmethyl)-5,6-bis(2-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-(Cyclobutylmethyl)-5,6-bis(2-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; N-cyclohexyl-5,6-bis(2-fluoro-4-hydroxyphenyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(2-chloro-4-hydroxyphenyl)-N-isopentyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(2-chloro-4-hydroxyphenyl)-N-(cyclopropylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(2-chloro-4-hydroxyphenyl)-N-(cyclobutylmethyl)-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide; 5,6-Bis(2-chloro-4-hydroxyphenyl)-N-cyclohexyl-N-(4-methoxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonamide.
3. The method for preparing the oxygen-bridged bicyclic-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents as claimed in claim 1 or 2, characterized in that: The steps include: S1. Synthesizing 3,4-bis(4-hydroxyphenyl)-furan, or synthesizing 3,4-bis(4-hydroxyphenyl)-furan containing different halogen substitutions; S2. Synthesis of vinylsulfonamide derivatives; S3. The 3,4-bis(4-hydroxyphenyl)-furan or 3,4-bis(4-hydroxyphenyl)-furan containing different halogen substitutions synthesized in step S1 is subjected to a diene synthesis reaction with the ethylene sulfonamide derivative synthesized in step S2 to obtain an oxygen-bridged bicyclo-[2.2.1]-heptene compound containing different sulfonamide nitrogen atom substituents.
4. The preparation method according to claim 3, characterized in that: In step S1, the synthesis route of 3,4-bis(4-hydroxyphenyl)-furan is as follows: 1) Synthesis of p-methoxybromoacetophenone Weigh p-methoxyacetophenone, p-toluenesulfonic acid and N-bromosuccinimide in a reaction container, add dichloromethane to dissolve, react the dissolved and mixed reactants at room temperature, monitor whether the reaction is complete by TLC thin-layer chromatography, desolventize after the reaction is complete, add ethyl acetate to dissolve, wash with 2N dilute hydrochloric acid, saturated sodium bicarbonate and saturated sodium chloride in sequence, dry the organic layer with anhydrous NaSO4, filter and spin-dry to obtain a crude product, and purify it by column chromatography to obtain a white solid compound 2, i.e. p-methoxybromoacetophenone; 2) Synthesis of 2-(4-methoxyphenyl)-2-carbonylethyl-2-(4-methoxyphenyl) acetate Weigh p-methoxybromoacetophenone and p-methoxyphenylacetic acid in a reaction container, add anhydrous acetonitrile to dissolve, slowly add anhydrous triethylamine dropwise, continue the reaction at room temperature, monitor whether the reaction is complete by TLC thin-layer chromatography, evaporate acetonitrile and triethylamine after the reaction is complete, add ethyl acetate to dissolve, wash with 2N dilute hydrochloric acid, saturated sodium bicarbonate and saturated sodium chloride successively, dry the organic layer with anhydrous sodium sulfate, filter and spin-dry to obtain a crude product, and purify it by column chromatography to obtain a yellow solid compound 4, i.e. 2-(4-methoxyphenyl)-2-carbonylethyl-2-(4-methoxyphenyl) acetate; 3) Synthesis of 3,4-di(4-methoxy-phenyl)furan-2-one Anhydrous and oxygen-free operation was performed. Under argon, 2-(4-methoxyphenyl)-2-carbonylethyl-2-(4-methoxyphenyl) acetate was weighed into a reaction vessel, anhydrous dimethyl sulfoxide was added to dissolve, 80% NaH was slowly added dropwise, and the reaction was carried out at 25°C. TLC thin-layer chromatography was used to monitor whether the reaction was complete. After the reaction was complete, 2N dilute hydrochloric acid was added to quench the reaction. The reaction solution was extracted with ethyl acetate, the organic layer was dried over anhydrous NaSO4, and the solvent was removed under reduced pressure to obtain a crude product, which was then purified by silica gel column to obtain compound 5, i.e., 3,4-di(4-methoxy-phenyl)furan-2-one; 4) Synthesis of 3,4-bis(4-hydroxy-phenyl)furan-2-one Anhydrous and oxygen-free operation was performed. Under argon, 3,4-di(4-methoxy-phenyl)furan-2-one was weighed into a reaction vessel, and dichloromethane was added to dissolve it. BBr3 was added at -20°C and reacted for 12 hours. Water was added to quench the reaction. The reaction solution was extracted with ethyl acetate and washed with saturated NaHCO3 solution. The organic layer was dried over anhydrous NaSO4 and desolvated under reduced pressure to obtain a crude product, which was then purified by silica gel column to obtain compound 6, i.e., 3,4-di(4-hydroxy-phenyl)furan-2-one. 5) Synthesis of 3,4-bis(4-hydroxy-phenyl)furan Anhydrous and oxygen-free operation was performed under argon. 3,4-di(4-hydroxy-phenyl)furan-2-one was weighed into a reaction vessel, diisobutyl hydride was added at -78°C for 12 hours, and then 4% H2SO4 was added to quench the reaction. The reaction solution was extracted with ethyl acetate and washed with saturated NaCl solution. The organic layer was dried over anhydrous NaSO4 and desolvated under reduced pressure to obtain a crude product, which was then purified on a silica gel column to obtain compound 7, i.e., 3,4-di(4-hydroxy-phenyl)furan.
5. The preparation method according to claim 3, characterized in that: In step S1, the synthesis route of 3,4-bis(4-hydroxyphenyl)-furan containing different halogen substitutions is as follows: 1) Synthesis of 3,4-dibromofuran Weigh (E)-3,4-dibromohex-3-ene-1,6-diol, add potassium dichromate and concentrated sulfuric acid, and then perform steam distillation to obtain compound 9, i.e., 3,4-dibromofuran; 2) Synthesis of halogen-substituted 3,4-bis(4-methoxyphenyl)-furan Weigh 3,4-dibromofuran and the corresponding halogen-substituted p-methoxyphenylboronic acid into a reaction container, add a palladium catalyst and anhydrous tetrahydrofuran, heat to reflux, and monitor whether the reaction is complete by TLC thin-layer chromatography. After the reaction is complete, distill off the tetrahydrofuran, add ethyl acetate to dissolve, wash with 2N dilute hydrochloric acid, saturated sodium bicarbonate and saturated sodium chloride in turn, dry the organic layer with anhydrous sodium sulfate, filter and spin-dry to obtain a crude product, and purify it by column chromatography to obtain the corresponding compounds 11a~11d, i.e., halogen-substituted 3,4-di(4-methoxyphenyl)-furan; 3) Synthesis of halogen-substituted 3,4-bis(4-hydroxyphenyl)-furan: The operation was carried out in anhydrous and oxygen-free conditions. Under argon, halogen-substituted 3,4-di(4-methoxyphenyl)-furan was weighed into a reaction vessel, dichloromethane was added to dissolve it, BBr3 was added at -20°C and reacted for 12 hours, water was added to quench the reaction, the reaction solution was extracted with ethyl acetate, and washed with saturated NaHCO3 solution, the organic layer was dried over anhydrous NaSO4, and the solvent was removed under reduced pressure to obtain a crude product, which was then purified on a silica gel column to obtain compounds 12a~12d, i.e. halogen-substituted 3,4-di(4-hydroxyphenyl)-furan.
6. The preparation method according to claim 3, characterized in that: In step S2, the synthesis route of the vinylsulfonamide derivative is as follows: 1) Synthesis of N-phenylacetamide compounds 15a-15c Weigh p-methoxyaniline and acid anhydride compounds 14a-14c into a single-mouth bottle, add dichloromethane to dissolve, slowly add pyridine, continue the reaction at room temperature, and use TLC thin-layer chromatography to monitor whether the reaction is complete. After the reaction is complete, remove the solvent under reduced pressure to obtain a crude product, and purify it with a silica gel column to obtain N-phenylacetamide compounds 15a-15c; 1) Synthesis of N-alkylaniline compounds 16a to 16d Under argon protection, N-phenylacetamide compounds 15a-15c were weighed into a double-necked bottle, anhydrous tetrahydrofuran was added to dissolve, borane-tetrahydrofuran was slowly added dropwise at 0°C, the temperature was slowly raised to 60°C and reacted for 24 hours, methanol was added to quench the reaction, the reaction solution was decompressed and desolventized to obtain a crude product, which was purified by silica gel column to obtain a white oily substance, namely N-alkylaniline compounds 16a-16d; 2) Synthesis of sulfonamide dienophiles 17a-17d The corresponding N-alkylaniline compounds 16a-16d were weighed and dissolved in dichloromethane, 2-chloroethanesulfonyl chloride was slowly added at 0°C, and after reacting for 10 minutes, a 20% sodium hydroxide aqueous solution was slowly added dropwise, and after reacting at room temperature for 24 hours, the solvent was removed under reduced pressure to obtain a crude product, which was purified by a silica gel column to obtain sulfonamide dienophile compounds 17a-17d; 3) Synthesis of sulfonamide dienophile compound 18 Weigh p-methoxyaniline and dissolve it in dichloromethane. Slowly add 2-chloroethanesulfonyl chloride at 0°C. After reacting for 10 minutes, slowly add 20% sodium hydroxide aqueous solution dropwise. After reacting at room temperature for 24 hours, remove the solvent under reduced pressure to obtain a crude product. Purify it on a silica gel column to obtain sulfonamide dienophile compound 18. 4) Synthesis of sulfonamide dienophile compounds 20a-20i The sulfonamide dienophile compound 18 was weighed and dissolved in N,N-dimethylformamide, potassium carbonate was added, and then the corresponding bromoalkanes 19a-19i were slowly added. After reacting at 60°C for 24 hours, the solvent was removed under reduced pressure to obtain a crude product, which was purified by a silica gel column to obtain the sulfonamide dienophile compounds 20a-20i; 5) Synthesis of sulfonamide dienophile compounds 22a-22c The corresponding amine compounds 21a~21c were weighed and dissolved in dichloromethane, 2-chloroethanesulfonyl chloride was slowly added at 0°C, and after reacting for 10 minutes, a 20% sodium hydroxide aqueous solution was slowly added dropwise. After reacting at room temperature for 24 hours, the solvent was removed under reduced pressure to obtain a crude product, which was purified by silica gel column to obtain sulfonamide dienophile compounds 22a~22c.
7. The preparation method according to claim 6, characterized in that: In step S3, the synthesis route of the oxygen-bridged bicyclic-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents is as follows: Among them, R1 is R2 is The synthesized 3,4-di(4-hydroxy-phenyl)furan and any one of the ethylenesulfonamide derivatives 17a-17c, 20a-20i, 22a-22c are dissolved in tetrahydrofuran and reacted at 90°C in one step to prepare oxygen-bridged bicyclo-[2.2.1]-heptene compounds 23a-23o with different sulfonamide nitrogen atom substituents.
8. The preparation method according to claim 6, characterized in that: In step S3, the synthesis route of the oxygen-bridged bicyclic-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents is as follows: The synthesized 3,4-di(4-hydroxyphenyl)-furan containing different halogen substitutions and any one of the ethylenesulfonamide derivatives 17c, 20e, 20f, 20g are dissolved in tetrahydrofuran and reacted at 90°C in one step to prepare oxygen-bridged bicyclo-[2.2.1]-heptene compounds 24a~24p containing different sulfonamide nitrogen atom substituents.
9. Use of the oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents as claimed in claim 1 or 2 and their pharmaceutically acceptable salts in the preparation of anti-breast cancer drugs.
10. The use according to claim 9, characterized in that The anti-breast cancer drug comprises one or more pharmaceutically acceptable carriers or excipients of the oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing different sulfonamide nitrogen atom substituents.
Citation Information
Patent Citations
Oxo-bridged bicyclo-heptylene sulfonamides compound containing different alkyl chain lengths, as well as preparation method and application thereof
CN108864127A
Oxygen bridge bicyclo-[2.2.1]-heptene compound containing different functional side chain structures, as well as preparation and application thereof
CN109942595A
Proteolytic targeted chimeric compound taking oxygen bridge bicycloheptene compound as estrogen receptor ligand as well as preparation method and application
CN111704648A
